NOS1AP and Alzheimer disease: nNOS–CAPON blockers combined with memantine, a NMDAR blocker used in severe Alzheimer's disease, might confer more beneficial effects than memantine or nNOS–CAPON blockers alone, especially in the early stage of disease.